RecruitingPhase 1NCT06978920

A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease

A Phase I, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection in the Treatment of Subjects With Parkinson's Disease


Sponsor

Nuwacell Biotechnologies Co., Ltd.

Enrollment

48 participants

Start Date

Jun 6, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.


Eligibility

Min Age: 40 YearsMax Age: 75 Years

Inclusion Criteria5

  • Ages between 40 and 75 years;
  • Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;
  • Disease history over 5 years;
  • Stable dose of dopamine treatment;
  • Able to undergo PET/CT/MRI detection;

Exclusion Criteria6

  • Patients who have previously undergone brain surgery;
  • Past use of stem cell therapy or participation in stem cell clinical research;
  • Cognitive impairment;
  • History of mental disorders;
  • Patients with other serious systemic diseases;
  • Past or current metastatic malignant tumors.

Interventions

DRUGAllogeneic dopaminergic neural precursor cell(NCR201)

Bilateral implantation


Locations(1)

The First Affiliated Hospital of USTC

Hefei, Anhui, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06978920


Related Trials